| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Kymera Therapeutics, Inc. (KYMR) has 15 insiders with recent SEC Form 4 filings, including 5 buys and 18 sells. KYMR is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| 10% | 7.96M | $673.39M | - | |
| Dir | 3.97M | $336.40M | - | |
| Dir | 2.80M | $236.89M | - | |
| CEO | 679.2K | $57.49M | -30,000 | |
| CFO | 227.4K | $19.25M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Dec 8, 2025 | Mainolfi Nello71 | Chief Executive Officer | Sale+OE | 100,000 | $89.17 | $8,917,000.00 | -13.1% | -9.8% | - | |
| Dec 8, 2025 | Gollob Jared70 | Chief Medical Officer | Sale+OE | 49,307 | $88.67 | $4,371,832.54 | -6.3% | -9.8% | - | |
| Oct 29, 2025 | Mainolfi Nello71 | Chief Executive Officer | Sale+OE | 30,000 | $60.99 | $1,829,736.91 | -1.5% | +20.2% | - | |
| Oct 15, 2025 | Gollob Jared70 | Chief Medical Officer | Sale+OE | 59,576 | $61.42 | $3,659,253.94 | -10.7% | +17.9% | - | |
| Oct 13, 2025 | Albers Jeffrey W.70 | Director | Sale+OE | 5,000 | $59.19 | $295,949.00 | -100% | +22.0% | - | |
| Oct 13, 2025 | Gollob Jared70 | Chief Medical Officer | Sale+OE | 3,114 | $60.00 | $186,840.00 | -2.6% | +22.0% | - | |
| Sep 17, 2025 | Jacobs Bruce N.74 | Chief Financial Officer | Sale+OE | 79,220 | $50.00 | $3,961,380.26 | -25.8% | +75.0% | - | |
| Sep 16, 2025 | Mainolfi Nello71 | Chief Executive Officer | Sale+OE | 30,000 | $49.00 | $1,470,000.00 | -4.3% | +75.6% | - | |
| Jun 30, 2025 | Baker Bros. Advisors LP59 | Director | Buy | 655,500 | $44.00 | $28,842,000.00 | +10.9% | +34.1% | - | |
| Jun 30, 2025 | Bvf Partners L P/il60 | Director, See Remarks And Footnotes | Buy | 317,167 | $44.00 | $13,955,348.00 | +6.3% | +34.1% | - |